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Introduction:  Topical  application  of  tranexamic  acid to  the  knee  joint  before  closure  in  total  knee arthro-
plasty  reduces  postoperative  bleeding  without  increase  in  complication.  However,  it is unknown  the
effectiveness  of  topic  TXA  performed  with  other  topical  medications,  like  povidone-iodine  solution.
Materials  and  methods:  One  hundred  and  twenty-ﬁve  patients  were  randomized  to  receive  100  mL  of
povidone-iodine  solution  (control:  group  A)  or 1.5  (group  B)  and  3.0 g (group  C) of topical  TXA in  povidone-
iodine  solution  applied  into  the knee  before  closure  in total knee  arthroplasty.
Results:  The  patients  in  the  TXA  groups  had  higher  mean  postoperative  hemoglobin  levels  (P  =  0.01  and
P =  0.03 in  groups  B and  C, respectively)  and  a  reduced  postoperative  blood  loss  in  the  TXA  groups  (P  =  0.07
and P =  0.09  in groups  B and  C,  respectively).  No signiﬁcant  complications  were  observed.
Discussion:  In this  study,  topical  application  of  tranexamic  acid  after  total  knee  arthroplasty  together
with  povidone-iodine  solution  results  in  higher  postoperative  hemoglobin  levels  and  lower  blood  loss
compared  with  those  in the  control  group  without  other  complications.
Level  of evidence:  I – I: high-powered  prospective  randomized  trial.
©  2014  Elsevier  Masson  SAS.  All  rights  reserved.. Introduction
Several authors have published reports describing a reduction
n blood loss and transfusion rates following total knee arthroplasty
TKA) after using an anti-ﬁbrinolytic agent: tranexamic acid (TXA)
1]. This concern came to the fact that postoperative blood loss asso-
iated with TKA ranges from 1450 to 1790 mL,  causing anaemia
nd other complications [2–5]. Blood transfusion is necessary in
0–38% of these patients [6–8]. The major cause of postoperative
lood loss following TKA is attributable to both surgical trauma and
ocal ﬁbrinolysis, primarily after tourniquet release at the end of the
rocedure [9].Topical TXA application is a medication with minimal systemic
bsorption and results in an important and effective decrease
n bleeding [9–12]. However, it is unknown the effectiveness of
∗ Corresponding author. Hospital Madre Teresa, Av Raja Gabaglia 1002, 30441-070
elo Horizonte, MG,  Brazil. Tel.: +55 3 198 185 808.
E-mail addresses: luciohcj@gmail.com (L.H. Carvalho Jr.), dufrois@hotmail.com
E. Frois Temponi).
http://dx.doi.org/10.1016/j.otsr.2014.10.013
877-0568/© 2014 Elsevier Masson SAS. All rights reserved.topic TXA performed simultaneously with other topical medica-
tions, like povidone-iodine solution. Povidone-iodine solution is
safe, inexpensive, simple to use, and readily available within most
operating rooms; in addition, it has broad-spectrum bactericidal
activity that includes methicillin-resistant Staphylococcus aureus
[13–17]. Brown et al. reported that Betadine® (povidone-iodine
solution) lavage may  represent a reasonable way  (0.97% to 0.15%
P = 0.04) of reducing acute postoperative deep infection in TKA
[15].
The main objective of this study was to assess the efﬁcacy of
topical TXA application used together with povidone-iodine solu-
tion after TKA, secondarily analysing the effects of this agent on
haematimetric indices and postoperative blood loss. Our hypothe-
sis was that in conjunction with povidone-iodine solution, TXA had
an antibibrinolytic effect.
2. Material and methodsA total of 125 patients undergoing TKA in Hospital Madre
Teresa between 2012 and 2013 by a single surgeon (L.H.C. Jr.)
were enrolled in this prospective, randomised, placebo-controlled
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•Fig. 1. Flow diagram indicating the number of pa
tudy (Fig. 1). The Ethical Committee of the Hospital Madre
eresa approved the details of this study, and written informed
onsent was obtained from each participant before starting this
tudy (CAAE–Brazilian Ministry Health 05286512.0.0000.5127). No
nancial incentives were offered to encourage subjects to partici-
ate.
All adult patients who were scheduled for a primary TKA at Hos-
ital Madre Teresa were eligible for inclusion. Exclusion criteria
ncluded the following: allergy to TXA or povidone-iodine solution,
reoperative anaemia, refusal of blood products, preoperative use
f anticoagulants (acetylsalicylic acid, enoxaparin, or any other, oral
r intravenous, agent), ﬁbrinolytic disorders, coagulopathy, arte-
ial or venous thromboembolic disease and pregnancy. Moreover,
he following patients were excluded from the study: patients with
ajor comorbidities, such as ischaemic heart disease, patients with
 history of myocardial infarction and those with severe pulmonary
isease.
The doses chosen for the current investigation were based on
revious studies of topical TXA in patients undergoing TKA, show-
ng efﬁcacy with doses of 1.5 g and 3 g for reducing the bleeding
9,10,12]. A diluted povidone-iodine solution (Betadine® solu-
ion – 0.35%) was used together and in the same time at the end of
rocedure for all groups, as shown by Brown et al. [15]. Patients in
his study were randomised into three groups using a computerized
rogram and were administered TXA as follows:group A patients (control) received Betadine® solution (0.35%)
(200 ml  – 0.35%); assessed and included at each stage of the trial.
• group B patients received1.5 g (100 mg/mL) TXA (Transamin®,
NIKKHO, Rio de Janeiro, Brazil) in Betadine solution (200 ml –
0.35%);
• group C patients received 3 g TXA (Transamin®, NIKKHO, Rio de
Janeiro, Brazil) in Betadine solution (200 ml  – 0.35%).
No control group was  used with isolated TXA solution due
to existence of data in the literature to substantiate the reduc-
tion in bleeding with this solution alone in the same doses used
[9,11,12,18–21].
All patients received a spinal anaesthesia [12–15 mg  isobaric
bupivacaine (0.5%)] with a femoral and sciatic nerve block [125 mg
ropivacaine (0.5%) associated to 75 g of clonidine] guided by ultra-
sonography for postoperative analgesia. All the procedures were
performed using pneumatic tourniquet around the upper part of
the thigh with a pressure of 350 mmHg  A midline skin and medial
parapatellar capsular incision was  made to expose the knee joint.
An identical type and appropriately sized, posterior stabilized knee
prosthesis was  used in every patient (NexGen – Zimmer®, Warsaw,
Indiana, United States). After all components were implanted, the
joint was thoroughly irrigated and the study medication (TXA) with
Betadine solution (200 ml  – 0.35%) was  applied to the open joint
surfaces and was  left in contact with the tissues for ﬁve minutes,
as described by Wong et al. [9]. The surgeon subsequently suc-
tioned away excess of solution by placing the suction tip without
touching the joint or the surrounding tissue surfaces. The wound
was closed and a 3.2 mm-diameter drains without suction was uti-
lized. The tourniquet was  released only after wound closure. To
prevent venous thromboembolism, patients received enoxaparin
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Table  1
Demographic and clinical characteristics of the patients.
Group A Group B Group C P
Site (right/left) R25 L15 R16 L26 R22 L16 ns
Sex  (male/female) M 10 F 30 M 18 F 24 M 7 F 31 ns
Age  (year) 69.3 ± 6 70.8 ± 6.5 70 ± 8.2 ns
Weight (kg) 80.6 ± 13 81.3 ± 11.9 79.4 ± 13.7 ns
Height (cm) 1.64 1.66 ± 0.09 1.62 ± 0.09 ns
Body mass index (kg/m2) 29.9 29.5 30.2 ns
T
P
(
a
s
i
p
d
e
t
e
c
d
f
p
e
o
m
h
o
h
l
e
p
b
t
1
t
3
a
s
d
a
Table 3
Blood loss, packed red blood cell transfusion, drain volume, thromboembolic events
and  acute infections after TKA.
Group A Group B Group C P
Drain volume 475 ± 210 552 ± 258 530 ± 201 ns
Blood loss (mL) 1324 ± 170 1066 ± 140 1057 ± 140 P < 0.05
Transfusion 2 1 2 ns
Deep vein thrombosis 2 0 1 ns
Pulmonary embolism 0 0 0 ns
Acute infection 0 0 0 ns
The P value represents the result of one-way analysis of variance for independent
means for continuous variables or the chi-square test for independent proportions
T
H
T
t
rhe values are presented as means ± standard deviation; ns: not signiﬁcant and
 < 0.05 = signiﬁcant.
40 mg/day/subcutaneous) for 10 days. The ﬁrst dose started 6 h
fter the procedure.
Demographic characteristics of patients in this study are pre-
ented in Table 1. Measured outcomes were haematimetrics
ndices (hemoglobin, haematocrit, prothrombin time, activated
artial thromboplastin time and international normalised ratio),
rain volume (mL), allogenic blood transfusion, thromboembolic
vents, total calculated blood loss and acute postoperative infec-
ion. The evaluation of these parameters was made by a single
xaminer (E.F.T.) blinded to the patient group in question. The
alculation of blood loss was done according to the formula
escribed by Good et al. [4]. This formula analyses the dif-
erence between the preoperative hemoglobin and the lowest
ostoperative hemoglobin during the hospital stay or the low-
st postoperative hemoglobin prior to blood transfusion. Based
n hemoglobin balance the total calculated blood loss was esti-
ated.
The criteria for transfusion of blood products included
emoglobin levels < 8.5 g/dL, intolerable symptoms of anaemia
r any organ dysfunction, or all together. Daily postoperative
emoglobin levels were measured for three days, and the lowest
evels were utilized for total calculated blood loss. Patients were
xamined daily for clinical symptoms of deep vein thrombosis. If a
atient was symptomatic, a Doppler ultrasound was  performed for
oth legs. Surgical drains were used for 24 h after surgery, and all
he volume collected was registered. All patients were followed for
2 weeks after surgery to assess for clinical symptoms of deep vein
hrombosis and acute infection.
. Statistical analyses
The distribution of potential confounders between study groups
nd the primary and secondary outcomes were assessed using
ummary statistics to include means, weighted means, standard
eviations and 95% conﬁdence intervals for quantitative data
nd frequencies and percentages for qualitative data. Continuous
able 2
ematimetric indices.
Group A Group
Pre-haematocrit 41.5 ± 2.6 41.8 ±
Post-haematocrit 33 ± 2.9 34.8 ±
Pre-platelet count 240.562 ± 54.700 223.83
Post-platelet count 200.937 ± 50.409 188.28
Pre-haemoglobin 13.8 ± 0.8 14 ± 1
Post-haemoglobin 10.9 ± 0.9 12 ± 1
Pre-APT  29.3 ± 4 28.9 ±
Post-APT 31.6 ± 1.4 32.6 ±
Pre-PT  13.6 ± 1.3 14 ± 3
Post-PT  16.4 ± 0.9 16.3 ±
Pre-INR 1.1 ± 0.08 1 ± 0.1
Post-INR 1.2 ± 0.08 1.2 ± 0
he P value represents the result of one-way analysis of variance for independent means fo
he  three groups. The values are presented as means ± standard deviation. ATP: activated
atio;  ns not signiﬁcant and P < 0.05 = signiﬁcant.that included the three groups. The values are presented as means ± standard devi-
ation; ns not signiﬁcant and P < 0.05 = signiﬁcant.
variables were compared using one-way analysis of variance,
and categorical variables were compared with the use of the
chi2 and ANOVA test. The following were assumed: standard
effect size (d) = 0.36; the level of alpha (two-tailed) = 0.05; and
power = 0.8. In addition, we assumed the standard deviation
within each group to be 14 g/dL, described by previous studies
[9]. The sample size was  increased by 20% to compensate for
expected dropouts, which were a minimum of 33 patients per
group.
4. Results
Patients in low-dose and high-dose TXA groups presented
higher mean postoperative hemoglobin levels compared with
those in the control group (P = 0.01 and P = 0.03 in groups B and
C, respectively). There was  no difference between the low-dose
(1.5 g) and high-dose (3 g) TXA groups regarding postoperative
hemoglobin levels (P = 0.3). Any other signiﬁcant difference was
observed in haematimetric indices between the three groups. There
was a trend toward better results in postoperative haematocrit lev-
els in the TXA groups as compared with the control group (P = 0.07
and P = 0.09 in groups B and C, respectively; Table 2), although no
statistically difference exists.
The mean drain volume was similar for all the groups. However,
the mean of total calculated postoperative blood loss was signiﬁ-
cantly reduced in the 1.5 g and 3 g TXA groups when compared with
the corresponding value in the control group. There was no dif-
ference between the low-dose (1.5 g) and high-dose (3 g) groups.
Further, the mean of drainage, the frequency of thromboembolic
manifestations and allogenic blood transfusion was similar in the
three groups. None acute infection was observed in the three groups
(Table 3).
 B Group C P
 3.9 41.8 ± 3.5 ns
 3.7 34.7 ± 3 ns
3 ± 55.825 219.315 ± 55.703 ns
5 ± 45.263 189.473 ± 53.695 ns
.4 13.9 ± 1.5 ns
.6 11.7 ± 1.2 P < 0.05
 5.5 30.7 ± 4.46 ns
 2.4 32.7 ± 1.9 ns
.7 13.4 ± 1.4 ns
 1 16.3 ± 1.3 ns
 1 ± 0.05 ns
.09 1.2 ± 0.1 ns
r continuous variables or the chi2 test for independent proportions which included
 partial thromboplastin time; PT: prothrombin time; IRN: international normalized
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. Discussion
To our knowledge, this is the ﬁrst study analysing both topical
olutions together in TKA and the effects of TXA on haemati-
etric indices and postoperative blood loss. The most important
nding of this study is that topical application of TXA after TKA
ogether with Betadine solution results in higher postoperative
aemoglobin levels and lower blood loss compared with those in
he control group without others complications, as seen in studies
sing isolated topical TXA [9,11,12,18–21]. A signiﬁcant difference
as noted in the haematimetric indices, with 10.2% higher post-
perative haemoglobin levels in both TXA groups with Betadine
olution compared with those in the control group. Moreover, a
ecreased blood loss of 20% was observed in both TXA groups when
ompared with the control group. Attention should be given to the
act that these values have been found despite similar drainage for
ll. This may  due to loss of other ﬂuids than blood through the drain.
owever, the need for blood transfusion was similar in the three
roups (but there was only one or two transfusions according to
he groups) and no increase was observed in symptomatic throm-
oembolism. It is difﬁcult to assess the rate of infection on such
hort series, although no acute infection was observed.
The mode of action of TXA is through competitive, reversible
lockade of lysine-binding sites on plasminogen. In addition, the
lockade induced by this agent results in the dissociation of plas-
inogen from ﬁbrin and thus the inhibition of ﬁbrinolysis. In the
peciﬁc case of topical application, the TXA acts directly on the
icrovasculature and clot stabilization, thus reducing local bleed-
ng. Changes in prothrombin and activated partial thromboplastin
ime must be measured when this agent is administered [18–23].
u et al. published the results of a meta-analysis evaluating the
afety and efﬁcacy of venous TXA in patients undergoing TKA. In
heir report, 15 randomised controlled trials met  their inclusion
riteria and were reviewed. They reported that the amount of blood
oss and number of blood transfusions decreased signiﬁcantly with
ntravenous TXA administration. Furthermore, TXA administration
id not produce any signiﬁcant differences in the prothrombin
ime, activated partial thromboplastin time, deep vein thrombo-
is or pulmonary embolism [23]; moreover, Alshryda et al. reached
imilar conclusions as well. They identiﬁed 19 clinical trials sat-
sfying their admission criteria and reviewed their results. Their
onclusion was that intravenous TXA signiﬁcantly reduced the pro-
ortion of patients requiring blood transfusion (RR 2.56; Pb 0.001)
20].
However, concerns regarding the safety of systemic TXA
dministration, the increased risk of thromboembolic events and
nteractions with others medications have hindered the wide adop-
ion of this medication in the setting of TKA [23,24]. Despite these
afety concerns, topical TXA application to the knee joint before TKA
losure might be a route of administration, which will reduce post-
perative bleeding without increasing the hypercoagulable state,
ssociated with this surgical procedure. Our report is not the ﬁrst
o attribute a potential beneﬁt to topical TXA administration dur-
ng primary TKA. Wind et al. reviewed their experience with 2269
onsecutive primary TKA procedures performed in 2069 patients
ver a period of 3.5 years. Intravenous TXA infusion demonstrated
 statistically signiﬁcant decrease in blood transfusion (P = 0.001),
s did topical TXA application (P = 0.019). The transfusion rate with-
ut TXA was 6.5% (120/1839) but was only 0.3% (1/330) with TXA
nfusion. There were no transfusions (0/130) observed with the
opical TXA use application [21]. Wong et al. reported a similar
tudy with topical TXA; in their study, topical TXA application
irectly into the surgical wound reduced postoperative bleeding
y 20–25% (300–400 mL), resulting in 16–17% higher postoperative
aemoglobin levels compared with that in the placebo group. No
linically signiﬁcant increase in complications could be identiﬁed inogy: Surgery & Research 101 (2015) 83–87
both groups [9]. Seo et al. also reported that intra-articular adminis-
tration of TXA seems to be more effective in terms of reducing blood
loss and transfusion frequency compared to intravenous adminis-
tration, reducing the chance of transfusion-associated side effects
and complications [11]. Li et al. [25] also reported that other topi-
cal product (ﬁbrin sealant) in TKA was effective and safe, reducing
haemoglobin decline, postoperative drainage volume, incidence of
haematoma and need for blood transfusion, and did not increase
the risk of complications, the same is not being reported by Massin
et al. [26]. In this study, ﬁbrin sealant was used in 31 patients who
were compared to the other 31 patients. In the control group, 48%
of patients required blood transfusions and the mean number of
units per patient used was 0.9 ± 1. In the ﬁbrin sealant group, 29% of
patients required blood transfusions and the mean number of units
was 0.6 ± 0.9. Despite these numbers, the differences (calculated
blood loss, blood transfusion and mean number of red blood cell
units used per patient) in ﬁbrin sealant group were not statistically
signiﬁcant [26].
The present study had several limitations. Besides the fact that
it was  conducted with a relatively larger number of patients than
previous studies, the study did not have the statistical power to
evaluate the assumption that TXA can decrease the frequency
of transfusion, despite decreased blood loss. With larger series
of patients, we  may  be able to ﬁnd the impact on the rate of
transfusion. Another limitation was  that screening for pulmonary
embolism or deep vein thrombosis was performed only using
Doppler ultrasound for symptomatic patients. We  did not specif-
ically assess the postoperative functional recovery to investigate
the relationship between hemoglobin levels and the outcome of
rehabilitation. Finally, the number of patients analyzed was small
to have signiﬁcance of the risk of acute infection after the TKA with
application of topical solution of TXA together with Betadine.
This study is important from a practical standpoint because
surgeons can consider incorporating the use of povidone-iodine
solution with topical TXA in their blood-saving protocols, due to
the fact that no interference with the effects of TXA has been noted
when the combined use of povidone-iodine solutions is used. Larger
series of patients may  be able to ﬁnd impact on the rate of infection
with povidone-iodine solution. Those beneﬁts can compensate the
extra time spend on it.
6. Conclusions
In this study, topical application of tranexamic acid after total
knee arthroplasty together with povidone-iodine solution results in
higher postoperative hemoglobin levels and lower blood loss com-
pared with those in the control group without other complications.
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